Blandt de patienter, der fik Hepsera, oplevede 53% af de HBeAg positive og 64% af de HBeAg negative patienter en bedring af leverbeskadigelsen, vurderet ved hjælp af en biopsi, sammenlignet med henholdsvis 25% og 33% af de patienter, der fik placebo.
Among those who took Hepsera, 53% of the HBeAg positive and 64% of the HBeAg negative patients had an improvement in liver damage assessed in a biopsy, compared with 25% and 33%, respectively, in the patients who took placebo.